Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — 14th World Federation of Hemophilia Global Forum (November 2025)
11 slides from Inovio Pharmaceuticals's conference presentation, Nov 14, 2025
Slide 1: Novel FVIII Secretion Via Non-Viral Vector DNA Medicine Platform
Novel FVIII Secretion Via Non-Viral Vector DNA Medicine Platform Laurent M. Humeau, Chief Scientific Officer November 14, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding o
Slide 3: INOVIO's DNA Medicines Platform
INOVIO's DNA Medicines Platform PRECISELY DESIGNED PROPRIETARY DEVICES MECHANISM OF ACTION TARGET PLASMIDS Antigen-specific cytotoxic HPV/Cancer T cells to treat disease Binding/neutralizing antibodies and T cells to prevent disease Infectious Disease Monoclonal antibodies to prevent/treat disease P
Slide 4: An Alternative to Viral-based Delivery for Long-Term In Vivo Protein Expression is Still Needed
An Alternative to Viral-based Delivery for Long-Term In Vivo Protein Expression is Still Needed • Long-term in vivo protein expression remains a sought-after goal for genetic disorders such as Hemophilia • Significant treatment improvements have been made, but hurdles remain - Pre-existing immunity
Slide 5: The Next Generation of DNA Medicine
DMAb/DPROTTM DNA ENCODED THERAPEUTIC PROTEINS The Next Generation of DNA Medicine MYOCYTE DMAb/DPROT technology enables in vivo production of proteins (e.g. mAbs or FVIII) • DNA is administered via CELLECTRA device to enable local expression of the genes coding for the proteins in the deltoid muscle
Slide 6: Proof-of-Concept Phase 1 Trial Evaluating DMAbs for COVID-19
Proof-of-Concept Phase 1 Trial Evaluating DMAbs for COVID-19 • Dose escalation study to evaluate the safety, tolerability and pharmacokinetic profile of mAb AZD5396 and mAb AZD8076 following EP delivery of optimized DMAb AZD5396 and DMAb AZD8076 • Published in Nature Medicine • Healthy Volunteer Stu
Slide 7: Ongoing Phase 1 Trial: Key Takeaways
Ongoing Phase 1 Trial: Key Takeaways • Well-tolerated: most common side effects were mild, temporary injection site reactions; no SAEs related to study drug DURABLE AND CONSISTENT DMAb EXPRESSION • Long-lasting in vivo antibody production: DMAb 1024 levels remained stable for 72 weeks in all partici
Slide 8: INOVIO DPROT Approach for Hemophilia A: HuFVIII Expressed and Functional in FVIII KO Mice
INOVIO DPROT Approach for Hemophilia A: HuFVIII is Expressed and Functional in FVIII KO Mice HuFVIII Activity 0.7 Activity (mean ± SEM) 0.6 Human FVIII (IU/ml) 0.5 • Demonstrates ectopic expression of huFVIII can be 0.4 achieved in skeletal muscle cells: activity reaching 50% over baseline 0.3 0.2 •
Slide 9: Inovio DPROT Approach for Hemophilia A: Phenotypic Correction of Bleeding in FVIII KO Mice
Inovio DPROT Approach for Hemophilia A: Phenotypic Correction of Bleeding in FVIII KO Mice Mouse tail clip model • pDNA-treated FVIII knockout mice showed significantly reduced bleeding time and blood loss compared to control (pGX0001-treated) knockout mice. • Bleeding control in pDNA-treated knocko
Slide 10: DMAb/DPROT Technology Has Potential as a New Treatment Paradigm in Rare Disease
DMAb/DPROT Technology Has Potential as a New Treatment Paradigm in Rare Disease • Platform has demonstrated ability for long-term protein secretion - Clinical PoC published in Nature Medicine1 • Safety data supports its future tolerability profile • Highly differentiated from existing platforms - Ab
Slide 11: Thank you.
Thank you. investor.relations@inovio.com communications@inovio.com
INOVIO Pharmaceuticals — 14th World Federation of Hemophilia Global Forum (November 2025) on 6ix